Skip to main content
SpringerLink
Log in

Use of recombinant erythropoietins for the treatment of anemia of chronic disease

  • Chapter
Erythropoietins and Erythropoiesis

Part of the book series: Milestones in Drug Therapy MDT ((MDT))

  • 613 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Schilling RF (1991) Anemia of chronic disease: A misnomer. Ann Intern Med 115: 572–573

    CAS  PubMed  Google Scholar 

  2. Means RT (1995) Pathogenesis of the anemia of chronic disease: A cytokine-mediated anemia. Stem Cells 13: 32–37

    PubMed  Google Scholar 

  3. Cash JM, Sears DA (1990) The spectrum of diseases associated with the anemia of chronic disease: A study of 90 cases. Am J Med 87: 638–644

    Google Scholar 

  4. Baer AN, Dessypris EN, Krantz SB (1990) The pathogenesis of anemia in rheumatoid arthritis. A clinical and laboratory analysis. Semin Arthritis Rheum 14: 209–223

    Google Scholar 

  5. Miller RK, Altz-Smith M (1982) Usefulness of serum ferritin in detecting iron deficiency in rheumatoid arthritis (RA). Arthritis Rheum 25: S114

    Google Scholar 

  6. Cartwright GE, Wintrobe MM (1952) The anemia of infection. XVII. A review. Adv Intern Med 5: 165–226

    CAS  PubMed  Google Scholar 

  7. Means RT (2000) The anaemia of infection. Ballieres Best Pract Res Clin Haematol 13: 151–162

    Google Scholar 

  8. Baynes RD, Flax H, Bothwell TH, Bezwoda WR, MacPhail AP, Atkinson P, Lewis D (1986) Haematological and iron-related measurements in active pulmonary tuberculosis. Scand J Haematol 36: 280–287

    CAS  PubMed  Google Scholar 

  9. Maartens G, Wilcox PA, Benatar SR (1990) Miliary tuberculosis: Rapid diagnosis, hematologic abnormalities, and outcome in 109 American adults. Am J Med 89: 291–296

    Article  CAS  PubMed  Google Scholar 

  10. Sandre RM, Shafran SD (1996) Infective endocarditis: Review of 135 cases over 9 years. Clin Infect Dis 22: 276–286

    CAS  PubMed  Google Scholar 

  11. Jansson LT, Kling S, Dallman PR (1986) Anemia in children with acute infections seen in a primary care pediatric outpatient clinic. Pediatr Infect Dis 5: 424–427

    CAS  PubMed  Google Scholar 

  12. van Iperen CE, Kraaijenhagen RJ, Biesma DH, Beguin Y, Marx JJ, van de Wiel A (1998) Iron metabolism and erythropoiesis after surgery. Br J Surg 85: 41–45

    PubMed  Google Scholar 

  13. Rodriguez RM, Corwin HL, Gettinger A, Corwin MJ, Gubler D, Pearl RG (2001) Nutritional deficiencies and blunted erythropoietin response as causes of the anemia of critical illness. J Crit Care 16: 36–41

    Article  CAS  PubMed  Google Scholar 

  14. Means RT, Allen J, Sears DA, Schuster SJ (1999) Serum soluble transferrin receptor and the prediction of marrow aspirate results in a heterogeneous group of patients. Clin Lab Haemat 21: 161–167

    Google Scholar 

  15. North M, Dallalio G, Donath AS, Melink R, Means RT (1997) Serum transferrin receptor levels in patients undergoing evaluation of iron stores: Correlation with other parameters, and observed versus predicted results. Clin Lab Haemat 19: 93–97

    CAS  Google Scholar 

  16. Abe Y, Muta K, Nishimura J, Nawata H (1992) Regulation of transferrin receptors by iron in human erythroblasts. Am J Hematol 40: 270–275

    CAS  PubMed  Google Scholar 

  17. Feelders RA, Vreugdenhil G, van Dijk JP, Swaak AJG, van Eijk HG (1993) Decreased affinity and number of transferrin receptors on erythroblasts in the anemia of rheumatoid arthritis. Am J Hematol 43: 200–204

    CAS  PubMed  Google Scholar 

  18. Huebers HA, Beguin Y, Pootrakul P, Einspahr D, Finch CA (1990) Intact transferrin receptors in human plasma and their relation to erythropoiesis. Blood 75: 102–107

    CAS  PubMed  Google Scholar 

  19. Ferguson BJ, Skikne BS, Simpson KM, Baynes RD, Cook JD (1992) Serum transferrin receptor distinguishes the anemia of chronic disease from iron deficiency anemia. J Lab Clin Med 19: 385–390

    Google Scholar 

  20. Chua E, Clague JE, Sharma AK, Horan MA, Lombard M (1999) Serum transferrin receptor assay in iron deficiency anaemia and anaemia of chronic disease in the elderly. QJM 92: 587–594

    Article  CAS  PubMed  Google Scholar 

  21. Punnonen K, Irjala K, Rajamaeki A (1997) Serum transferrin receptor and its ratio to serum ferritin in the diagnosis of iron deficiency. Blood 89: 1052–1057

    CAS  PubMed  Google Scholar 

  22. Jefferey MR (1953) Some observations on anemia in rheumatoid arthritis. Blood 8: 502–518

    Google Scholar 

  23. Vilcek J, Gray PW, Rinderknecht E, Sevastopoulos CG (1985) Interferon: A lymphokine for all seasons. Lymphokines 11: 1–32

    CAS  Google Scholar 

  24. Hooks JJ, Moutsopopoulos HM, Geis SA, Stahl NI, Decker JL, Notkins AC (1979) Immune interferon in the circulation of patients with autoimmune disease. N Engl J Med 301: 5–8

    CAS  PubMed  Google Scholar 

  25. Maury CPJ, Andersson LC, Teppo A-M, Partanen S, Javonen E (1988) Mechanism of anaemia in rheumatoid arthritis: Demonstration of raised interleukin-1β concentration in anaemic patients and of interleukin-1 mediated suppression of normal erythropoiesis and proliferation of human erythroleukemia (HEL) cells in vitro. Ann Rheum Dis 47: 972–978

    CAS  PubMed  Google Scholar 

  26. Balkwill F, Burke F, Talbot D, Tavernier J, Osborne R, Naylor S, Durbin H, Fiers W (1987) Evidence for tumor necrosis factor/cachectin production in cancer. Lancet 2: 1229–1232

    CAS  PubMed  Google Scholar 

  27. Teppo A-M, Maury CPJ (1987) Radioimmunoassay of tumor necrosis factor in serum. Clin Chem 33: 2024–2027

    CAS  PubMed  Google Scholar 

  28. Mauritz NJ, Holmdahl R, Jonsson R, Van der Meide PH, Scheynius A, Klarskug L (1988) Treatment with gamma-interferon triggers the onset of collagen arthritis in mice. Arthritis Rheum 31: 1297–1303

    CAS  PubMed  Google Scholar 

  29. Cartwright GE (1966) The anemia of chronic disease. Semin Hematol 3: 351–375

    CAS  PubMed  Google Scholar 

  30. Means RT, Krantz SB (1992) Progress in understanding the pathogenesis of the anemia of chronic disease. Blood 80: 1639–1647

    PubMed  Google Scholar 

  31. Davis D, Charles PJ, Potter A, Feldmann M, Maini RN, Elliott MJ (1997) Anaemia of chronic disease in rheumatoid arthritis: In vivo effects of tumour necrosis factor alpha blockade. Br J Rheumatol 36: 950–956

    Article  CAS  PubMed  Google Scholar 

  32. Allen DA, Breen C, Yaqoob MM, Macdougall IC (1999) Inhibition of CFU-E colony formation in uremic patients with inflammatory disease: Role of IFN-γ and TNF-α. J Invest Med 47: 204–211

    CAS  Google Scholar 

  33. Voulgari PV, Kolios G, Papadopoulos GK, Katsaraki A, Seferiadis K, Drosos AA (1999) Role of cytokines in the pathogenesis of anemia of chronic disease in rheumatoid arthritis. Clin Immunol 92: 153–160

    Article  CAS  PubMed  Google Scholar 

  34. Salvarini C, Casali B, Salvo D, Brunati C, Macchioni PL, Massai G, Lasagni D, Rivasi P, Portoli I (1991) The role of interleukin 1, erythropoietin, and red cell bound immunoglobulins in the anaemia of rheumatoid arthritis. Clin Exp Rheumatol 9: 241–246

    Google Scholar 

  35. Moldawer LL, Marano MA, Wei H, Fong Y, Silen ML, Kuo G, Manogue KR, Vlassara H, Cohen H, Cerami A et al. (1989) Cachectin/tumor necrosis factor alters red blood cell kinetics and induces anemia in vivo. FASEB J 3: 1637–1643

    CAS  PubMed  Google Scholar 

  36. Rice L, Alfrey CP, Driscoll T, Whitley CE, Hachey DL, Suki W (1999) Neoctyoloysis contributes to the anemia of renal disease. Am J Kidney Dis 33: 59–62

    CAS  PubMed  Google Scholar 

  37. Deliconstantinos G, Villitou V, Stavrides JC, Salemes N, Gogas J (1995) Nitric oxide and peroxynitrite production by human erythrocytes: A causative factor of toxic anemia in breast cancer patients. Anticancer Res 15: 1435–1446

    CAS  PubMed  Google Scholar 

  38. Erslev AJ, Caro J, Miller O, Silver R (1980) Plasma erythropietin in health and disease. Ann Lab Clin Sci 10: 250–257

    CAS  Google Scholar 

  39. Baer AN, Dessypris EN, Goldwasser E, Krantz SB (1987) Blunted erythropoietin response to anaemia in rheumatoid arthritis. Br J Haematol 66: 559–564

    CAS  PubMed  Google Scholar 

  40. Voulgarelis M, Kokori SI, Ioannidis JP, Tzioufas AG, Kyriaki D, Moutsopoulos HM (2000) Anaemia in systemic lupus erythematosus: Aetiological profile and the role of erythropoietin. Ann Rheum Dis 59: 217–222

    Article  CAS  PubMed  Google Scholar 

  41. Faquin WC, Schneider TJ, Goldberg MA (1992) Effect of inflammatory cytokines on hypoxiainduced erythropoietin production. Blood 79: 1987–1994

    CAS  PubMed  Google Scholar 

  42. Jelkmann W, Pagel H, Wolff M, Fandrey J (1991) Monokines inhibiting erythropoietin production in human hepatoma cultures and in isolated perfused rat kidneys. Life Sci 50: 301–308

    Google Scholar 

  43. Pieroni L, Foglietti MJ, Andreux JP, Albou D, Nafziger J (1997) Factors involved in the anaemia of chronic disorders in elderly patients. Gerontology 43: 326–334

    CAS  PubMed  Google Scholar 

  44. Tracey KJ, Wei H, Nanogue KR, Fong Y, Hesse DG, Nguyen HT, Kuo GC, Beutler B, Cotran RS, Cerami A et al. (1988) Cachectin/tumor necrosis factor induces cachexia, anemia, and inflammation. J Exp Med 167: 1211–1227

    Article  CAS  PubMed  Google Scholar 

  45. Roodman GD, Bird A, Hutzler D, Montgomery W (1987) Tumor necrosis factor-alpha and hematopoietic progenitors: Effects of tumor necrosis factor on the growth of erythroid progenitors CFU-E and BFU-E and the hematopoietic cell lines K562, HL60, HEL cells. Exp Hematol 15: 928–935

    CAS  PubMed  Google Scholar 

  46. Johnson CS, Cook CA, Furmanski P (1990) In vivo suppression of erythropoiesis by tumor necrosis factor-α (TNF-α): Reversal with exogenous erythropoietin (EPO). Exp Hematol 18: 109–113

    CAS  PubMed  Google Scholar 

  47. Johnson RA, Waddelow TA, Caro J, Oliff A, Roodman GD (1989) Chronic exposure to tumor necrosis factor in vivo preferentially inhibits erythropoiesis in nude mice. Blood 74: 130–138

    CAS  PubMed  Google Scholar 

  48. Maury CPJ (1987) Anaemia in rheumatoid arthritis: Role of cytokines. Scand. J Rheumatol 18: 3–5

    Google Scholar 

  49. Johnson CS, Keckler DJ, Topper MI, Braunschweigger PG, Furmanski P (1989) In vivo hematopoietic effect of recombinant interleukin-1alpha in mice: Stimulation of granulocytic, monocytic, megakaryocytic, and early erythroid progenitors; suppression of late stage erythropoiesis, and reversal of erythroid suppression with erythropoietin. Blood 73: 678–683

    CAS  PubMed  Google Scholar 

  50. Mamus SW, Beck-Schroeder SK, Zanjani ED (1985) Suppression of normal human erythropoiesis by gamma interferon in vitro: Role of monocytes and T-lymphocytes. J Clin Invest 75: 1496–1503

    CAS  PubMed  Google Scholar 

  51. Raefsky EL, Platanias LC, Zoumbos NC, Young NS (1985) Studies of interferon as a regulator of hematopoietic cell proliferation. J Immunol 135: 2507–2512

    CAS  PubMed  Google Scholar 

  52. Zanjani ED, McGlave PB, Davies SF, Bonisadre M, Kaplan ME, Sarosi GA (1982) In vitro suppression of erythropoiesis by bone marrow adherent cells from some patients with fungal infection. Br J Haematol 50: 479–490

    CAS  PubMed  Google Scholar 

  53. Sugimoto M, Wakabayashi Y, Hirose S, Takaku F (1987) Immunological aspects of the anemia of rheumatoid arthritis. Am J Hematol 25: 1–11

    CAS  PubMed  Google Scholar 

  54. Means RT, Dessypris EN, Krantz SB (1990) Inhibition of human colony-forming units erythroid by tumor necrosis factor requires accessory cells. J Clin Invest 86: 538–541

    CAS  PubMed  Google Scholar 

  55. Means RT, Krantz SB (1993) Inhibition of human erythroid colony-forming units by tumor necrosis factor requires beta interferon. J Clin Invest 91: 416–419

    CAS  PubMed  Google Scholar 

  56. Means RT, Dessypris EN, Krantz SB (1992) Inhibition of human erythroid colony-forming units by interleukin-1 is mediated by gamma interferon. J Cell Physiol 150: 59–64

    Article  CAS  PubMed  Google Scholar 

  57. Means RT, Krantz SB (1996) Inhibition of human erythroid colony-forming units by interferons α and β: Differing mechanisms despite shared receptor. Exp Hematol 24: 204–208

    CAS  PubMed  Google Scholar 

  58. Dai C-H, Price JO, Brunner T, Krantz SB (1998) Fas ligand is present in human erythroid colonyforming cells and interacts with Fas induced by interferon gamma to produce erythroid cell apoptosis. Blood 91: 1235–1242

    CAS  PubMed  Google Scholar 

  59. North M, Dallalio G, Means RT (1998) Effects of ceramide on human erythroid colony formation: Involvement in inhibition induced by gamma-interferon. Exp Hematol 26: 462a

    Google Scholar 

  60. Shami PJ, Weinberg JB (1996) Differential effects of nitric oxide on erythroid and myeloid colony growth from CD34+ human bone marrow cells. Blood 87: 977–982

    CAS  PubMed  Google Scholar 

  61. Taniguchi S, Dai C-H, Price JO, Krantz SB (1997) Interferon gamma downregulates stem cell factor and erythropoietin receptors but not insulin-like growth factor-I receptors in human erythroid colony-forming cells. Blood 90: 2244–2252

    CAS  PubMed  Google Scholar 

  62. Means RT, Krantz SB (1991) Inhibition of human erythroid colony forming units by gamma interferon can be corrected by recombinant human erythropoietin. Blood 78: 2564–2567

    CAS  PubMed  Google Scholar 

  63. Denz H, Fuchs D, Huber H, Nachbaur D, Reibnegger G, Thaler J, Werner ER, Wachter H (1990) Correlation between neopterin, interferon-gamma, and haemoglobin in patients with haematological disorders. Eur J Haematol 44: 186–189

    CAS  PubMed  Google Scholar 

  64. Alvarez-Hernandez X, Liceaga J, McKay IC, Brock JH (1989) Induction of hypoferremia and modulation of macrophage iron metabolism by tumor necrosis factor. Lab Invest 61: 319–322

    CAS  PubMed  Google Scholar 

  65. Rogers J, Lacroix L, Durmowitz G, Kasschau K, Andriotakis J, Bridges KR (1994) The role of cytokines in the regulation of ferritin expression. Adv Exp Med Biol 356: 127–132

    CAS  PubMed  Google Scholar 

  66. Peetre C, Gullberg U, Nilsson E, Olsson I (1986) Effects of recombinant tumor necrosis factor on proliferation and differentiation of leukemic and normal hemopoietic cells in vitro. Relation to cell surface receptors. J Clin Invest 78: 1694–1700

    CAS  PubMed  Google Scholar 

  67. Recalcati S, Taramelli D, Conte D, Cairo G (1998) Nitric oxide-mediated induction of ferritin synthesis in J774 macrophages by inflammatory cytokines: Role of selective iron regulatory protein-2 downregulation. Blood 91: 1059–1066

    CAS  PubMed  Google Scholar 

  68. Bertero MT, Caligaris-Cappio F (1997) Anemia of chronic disorders in systemic autoimmune diseases. Haematologia 82: 375–381

    CAS  Google Scholar 

  69. Domachowske JB (1997) The role of nitric oxide in the regulation of cellular iron metabolism. Biochem Molec Med 60: 1–7

    CAS  Google Scholar 

  70. Weiss G, Bogdan C, Hentze MW (1997) Pathways for the regulation of macrophage iron metabolism by the anti-inflammatory cytokines IL-4 and IL-13. J Immunol 158: 420–425

    CAS  PubMed  Google Scholar 

  71. Oria R, Sanchez L, Houston T, Hentze MW, Liew FY, Brock JH (1995) Effect of nitric oxide on expression of transferrin receptor and ferritin and on cellular iron metabolism in K562 human erythroleukemia cells. Blood 85: 2962–2966

    CAS  PubMed  Google Scholar 

  72. Watts RN, Richardson DR (2000) Examination of the mechanism of action of nitrogen monoxide on iron uptake from transferrin. J Lab Clin Med 136: 149–156

    Article  CAS  PubMed  Google Scholar 

  73. Engstedt L, Johannsson S, Strandeberg O (1966) Studies in anemia and plasma protein disturbance. Acta Med Scand 180: 92–106

    Google Scholar 

  74. Means RT, Olsen NJ, Krantz SB, Dessypris EN, Graber SE, Stone WJ, O’Neil VL, Pincus T (1989) Treatment of the anemia of rheumatoid arthritis with recombinant human erythropoietin: Clinical and in vitro studies. Arthritis Rheum 32: 638–642

    PubMed  Google Scholar 

  75. Takashima N, Kondo H, Kashwazaki S (1990) Suppressed erythropoietin response to anemia and efficacy of recombinant erythropoietin in the anemia of rheumatoid arthritis. J Rheumatol 17: 885–887

    Google Scholar 

  76. Pincus T, Olsen NJ, Russell IJ, Wolfe F, Harris R, Schnitzer T, Abels R, Boccagno J, Krantz SB (1990) Multicenter study of recombinant human erythropoietin in correction of anemia in rheumatoid arthritis. Am J Med 89: 161–168

    Article  CAS  PubMed  Google Scholar 

  77. Granolleras C, Branger B, Beau MC, Deschodt G, Alsabadani B, Shaldon S (1989) Experience with daily self-administered subcutaneous erythropoietin. Contrib Nephrol 76: 143–148

    CAS  PubMed  Google Scholar 

  78. Gudbjornsson B, Hallgren R, Wide L, Birgegard G (1992) Response of anemia in rheumatoid arthritis to treatment with subcutaneous recombinant human erythropoietin. Ann Rheum Dis 51: 747–752

    CAS  PubMed  Google Scholar 

  79. Peeters HR, Jongen-Lavrencic M, Vreugdenhil G, Swaak AJ (1996) Effect of recombinant human erythropoietin on anaemia and disease activity in patients with rheumatoid arthritis and anaemia of chronic disease: A randomised placebo controlled double blind 52 weeks clinical trial. Ann Rheum Dis 55: 739–744

    CAS  PubMed  Google Scholar 

  80. Nordstrom D, Lindroth Y, Marsal L, Hafstrom I, Heinrich C, Rantapaa-Dalqvist S, Engstrom-Laurent A, Friman C (1997) Availability of iron and degree of inflammation modifies the response to recombinant human erythropoietin when treating anemia of chronic disease in patients with rheumatoid arthritis. Rheumatol Int 17: 67–73

    CAS  PubMed  Google Scholar 

  81. Kaltwasser JP, Kessler U, Gottschalk R, Stucki G, Moller B (2001) Effect of recombinant human erythropoietin and intravenous iron on anemia and disease activity in rheumatoid arthritis. J Rheumatol 28: 2430–2436

    CAS  PubMed  Google Scholar 

  82. Dohil D, Hassal E, Wadsworth LD, Israel DM (1998) Recombinant human erythropoietin for treatment of anemia of chronic disease in children with Crohn’s disease. J Pediatr 132: 155–159

    CAS  PubMed  Google Scholar 

  83. Corwin HL, Gettinger A, Rodriguez RM, Gubler KD, Enny C, Colton T, Corwin MJ (1999) Efficacy of recombinant human erythropoietin in the critically ill patient: A randomized, double blind, placebo controlled trial. Crit Care Med 2: 2346–2350

    Google Scholar 

  84. Silverberg DS, Wexler D, Blum M, Keren G, Sheps D, Leibovitch E, Brosh D, Laniado S, Schwartz D, Yachinin T et al. (2000) The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalization. J Am Coll Cardiol 35: 1737–1744

    Article  CAS  PubMed  Google Scholar 

  85. Peeters HR, Jongen-Lavrencic M, Bakker CH, Vreugdenhil G, Breedveld FC, Swaak AJ (1999) Recombinant human erythropoietin improves health-related quality of life in patients with rheumatoid arthritis and anaemia of chronic disease; utility measures correlate strongly with disease activity measures. Rheumatol Int 18: 201–206

    Article  CAS  PubMed  Google Scholar 

  86. Ballard H, Rana J, Ackerman A, Merino R, Rosenoff S, Kastritsis C, Trout R, Chaudhaury M, Auerbach M (1999) Total dose infusion (TDI) of iron dextran (ID) optimizes erythropoietin (EPO) responsiveness in the anemia of cancer (CA). Proc Am Soc Clin Oncol 18: A2245

    Google Scholar 

  87. Kuhns WJ, Gubler CJ, Cartwright GE, Wintrobe MM (1950) The anemia of infection. XIV. Response to massive doses of intravenously administered saccharated oxide of iron. J Clin Invest 29: 1505–1513

    CAS  PubMed  Google Scholar 

  88. Bentley DP, Williams P (1982) Parenteral iron therapy in the anemia of rheumatoid arthritis. Rheumatol Rehab 21: 88–92

    CAS  Google Scholar 

  89. Auerbach M, Witt D, Toler W, Fierstein M, Lerner RG, Ballard H (1988) Clinical use of the total dose intravenous infusion of iron dextran. J Lab Clin Med 111: 566–570

    CAS  PubMed  Google Scholar 

  90. Thompson FL, Powers JS, Graber SE, Krantz SB (1991) Use of recombinant human erythropoietin to enhance autologous blood donation in a patient with multiple red cell allo-antibodies and the anemia of chronic disease. Am J Med 90: 398–400

    CAS  PubMed  Google Scholar 

  91. Goodnough LT, Marcus RE (1997) The erythropoietic response to erythropoietin in patients with rheumatoid arthritis. J Lab Clin Med 130: 381–386

    Article  CAS  PubMed  Google Scholar 

  92. Goodnough LT, Rudnik S, Price TH, Ballas SK, Collins ML, Crowley JP, Kosmin M, Kruskall MS, Lenes BA, Menitove JE et al. (1989) Increased preoperative collection of autologous blood with recombinant human erythropoietin therapy. N Engl J Med 321: 1163–1168

    CAS  PubMed  Google Scholar 

  93. Coccia MA, Cooke K, Stoney G, Pistillo J, Del Castillo J, Duryea D, Tarpley GA, Molineux G (2001) Novel erythropoiesis stimulating protein (darbepoetin alfa) alleviates anemia associated with chronic inflammatory disease in a rodent model. Exp Hematol 10: 1201–1209

    Google Scholar 

  94. Smith RE, Jaiyesima IA, Meza LA, Tchekmediyan NS, Chan D, Griffith H, Brosman S, Bukowski R, Murdoch M, Rarick M et al. (2001) Novel erythropoieisis stimulating protein (NESP) for the treatment of the anemia of chronic disease associated with cancer. Br J Cancer 84: 24–30

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Hematology/Oncology Division, Ralph H. Johnson Veterans Affairs Medical Center, Medical University of South Carolina, 903 CSB, 96 Jonathan Lucas Street, Charleston, SC, 29425, USA

    Robert T. Means Jr.

Authors
  1. Robert T. Means Jr.
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Amgen Inc, One Amgen Center Drive, Thousand Oaks, California, 91320, USA

    Graham Molineux , Mary Ann Foote  & Steven G. Elliott ,  & 

Rights and permissions

Reprints and permissions

Copyright information

© 2003 Birkhäuser Verlag/Switzerland

About this chapter

Cite this chapter

Means, R.T. (2003). Use of recombinant erythropoietins for the treatment of anemia of chronic disease. In: Molineux, G., Foote, M.A., Elliott, S.G. (eds) Erythropoietins and Erythropoiesis. Milestones in Drug Therapy MDT. Birkhäuser Basel. https://doi.org/10.1007/3-7643-7543-4_11

Download citation

Publish with us

Policies and ethics

Search

Navigation